<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126464</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000430705</org_study_id>
    <secondary_id>CSMC-00000244</secondary_id>
    <secondary_id>CSMC-4415/CR00000244</secondary_id>
    <secondary_id>ZENECA-CSMC-00000244</secondary_id>
    <secondary_id>CSMC-1B-03-7</secondary_id>
    <nct_id>NCT00126464</nct_id>
  </id_info>
  <brief_title>Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast</brief_title>
  <official_title>A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant (Faslodex) in Breast Ductal Carcinoma (DCIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      fulvestrant or tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor&#xD;
      cells. Giving fulvestrant or tamoxifen before surgery may be an effective treatment for&#xD;
      breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well giving fulvestrant or tamoxifen&#xD;
      works in treating postmenopausal women who are undergoing surgery for ductal carcinoma in&#xD;
      situ of the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of neoadjuvant fulvestrant, in terms of molecular&#xD;
           changes in markers of the estrogen pathway, cell proliferation and apoptosis, and the&#xD;
           epidermal growth factor pathway, in postmenopausal women with newly diagnosed ductal&#xD;
           carcinoma in situ of the breast.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of fulvestrant in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, pilot, multicenter study. Patients are&#xD;
      randomized to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral placebo once daily on days 1-21.&#xD;
&#xD;
        -  Arm II: Patients receive oral tamoxifen once daily on days 1-21.&#xD;
&#xD;
        -  Arm III: Patients receive fulvestrant intramuscularly (IM) on day 1.&#xD;
&#xD;
        -  Arm IV: Patients receive fulvestrant IM as in arm III but at a higher dose. In all arms,&#xD;
           treatment continues in the absence of disease progression or unacceptable toxicity. All&#xD;
           patients undergo surgical resection of the tumor on approximately day 21.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (25 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular markers of the estrogen pathway as measured by immunohistochemistry at 3 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mammographic breast density as measured by the Madena method at 3 weeks</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ductal carcinoma in situ (DCIS) of the breast&#xD;
&#xD;
               -  T0 disease&#xD;
&#xD;
               -  Newly diagnosed disease by minimally invasive biopsy (e.g., a vacuum-assisted&#xD;
                  large core tool [mammotome] or an equivalent method)&#xD;
&#xD;
          -  Biopsy tissue available for molecular marker analysis&#xD;
&#xD;
          -  Baseline mammography performed within the past 8 weeks&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, as defined by 1 of the following:&#xD;
&#xD;
               -  Age ≥ 60&#xD;
&#xD;
               -  Age ≥ 45 AND amenorrheic for &gt; 1 year with uterus intact&#xD;
&#xD;
               -  Underwent bilateral oophorectomy&#xD;
&#xD;
               -  Follicle-stimulating hormone and estradiol levels in postmenopausal range&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and/or SGPT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No history of deep vein thrombosis&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No history of pulmonary embolism&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Negative pregnancy test (if clinically indicated)&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No underlying medical, psychiatric, or social condition that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 6 months since prior hormonal therapy, including any of the following:&#xD;
&#xD;
               -  Antiestrogens&#xD;
&#xD;
               -  Estrogen&#xD;
&#xD;
               -  Selective estrogen-receptor modulators&#xD;
&#xD;
               -  Progestins&#xD;
&#xD;
               -  Aromatase inhibitors&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior therapy for DCIS&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustin Garcia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

